Prognostic value of serum ferritin in cancerous patients

Abstract

Author(s): Hadeel Riyadh Ibrahim*, Ahmed Jamal Jasim Alqaisi and Tarik M. Abdul Majeed Al-Bermani

Cancers are the second cause of mortality worldwide. Ferritin is a known iron protein found in high concentrations in cancerous patients. The study aimed to estimate ferritin levels in cancerous patients, determine the correlation between serum ferritin and chemotherapy (CHX). A cross-sectional hospitalbased study was carried out in AlKarama Teaching Hospital. Assessments of the studied samples will be conducted as a baseline setting and in a subsequent manner. A total of 50 newly diagnosed cancer patients before undergoing CHX regimens (13 male and 37 female) were included. The kit Ferritin (FTL) Human ELISA Kit was used. In this study, 74% females and 36% males were studied. The mean age of the sample of the study was 50.85 ± 12.59 years. The breast cancer females about 40% of patients. About 51.3% of females, their ferritin concentration were within a normal level, while 28.2% of females have a high level. After all cycles of CHX, 75.6% of females have normal concentrations. These results have significant differences among pre and post CHX (ANOVA=1.992, p=0.049). Among males, the results have no significant among pre and post CHX (ANOVA=0.162, p=0.057). Among gender, at setting status, there was a high significant difference between high concentrations of ferritin and females cancers when compared with males cancer (p=0.039). The mean of ferritin concentration was dropped gradually with subsequent cycles of CHX (185.25 ± 47.283 μg/L)>(75.64 ± 49.699 μg/L)>(72.89 ± 38.42 μg/L)>(65.31 ± 29.187 μg/L), respectively, with a high statistical association (p<0.0001). The high level of ferritin is associated with advanced or untreated malignancies. CHX caused dropping in serum ferritin in subsequent cycles rather than a single cycle. A high level of ferritin is more recorded in female malignancies in comparison with a male.

Share this article